Interleukin-1 haplotype and periodontal disease progression following therapy

J Clin Periodontol. 1999 Dec;26(12):810-3. doi: 10.1111/j.1600-051x.1999.tb02525.x.

Abstract

The purpose of this study was to assess the prognostic value of the IL-1 haplotype on the progression of periodontal disease following therapy. 48 adult patients with untreated periodontitis harboring Actinobacillus actinomycetemcomitans and/or Porphyromonas gingivalis were randomly assigned to receive full-mouth scaling alone (control) or in combination with systemic metronidazole plus amoxicillin and supragingival irrigation with chlorhexidine digluconate (test). All patients received supportive periodontal therapy at 3 to 6 months intervals. In 33 patients, lymphocyte DNA was analyzed for polymorphism in the IL-1A gene at position -889 and IL-1B gene at position +3953. Overall, 16 of 33 patients (7 of 17 test and 9 of 16 control) carried the IL-1 haplotype. 2 years following initial periodontal therapy, no differences in the survival rates of sites or teeth not exhibiting probing attachment loss of 2 mm or more compared to baseline, were found between patients who tested positive (85% sites, 53% teeth) and patients who tested negative (89% sites, 56% teeth) for the IL-1 haplotype. The results indicated that the IL-1 haplotype may be of limited value for the prognosis of periodontal disease progression following non-surgical periodontal therapy.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aggregatibacter actinomycetemcomitans / isolation & purification
  • Combined Modality Therapy
  • Disease Progression
  • Haplotypes / genetics*
  • Humans
  • Interleukin-1 / genetics*
  • Middle Aged
  • Periodontitis / blood
  • Periodontitis / genetics*
  • Periodontitis / microbiology
  • Periodontitis / therapy
  • Porphyromonas gingivalis / isolation & purification
  • Prognosis
  • Prospective Studies
  • Survival Analysis
  • Time Factors

Substances

  • Interleukin-1